ESMO Virtual 2020: Impact of immunotherapy on quality of life

In this video interview, Dr Jeffrey¬†Kirshner from the Haematology-Oncology Associates of Central New York Community Clinical Oncology Programme talks about a global review of data on quality of life in patients on immunotherapy that was presented at this year’s ESMO.¬† During the interview, Dr Kirshner mentions that quality of life is better with immunotherapy than […]

read more

Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab

In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated. One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, […]

read more

Monitoring treatment toxicities in patients with renal cell carcinoma

Drs Dan George and Tian Zhang from the Duke Prostate and Urologic Cancer Centre, Durham, USA, share their views on monitoring side effects to treatment of patients with renal cell carcinoma (RCC). Emphasis is placed on counselling patients on expectations and managing baseline co-morbidities. Maintaining a prescribed treatment schedule while focused on quality of life […]

read more
Showing all 3 results